• Lakewood-Amedex Biotherapeutics reported positive development data for its lead candidate Nu-3 as it moves toward a planned Phase 2 trial in mildly infected diabetic foot ulcers.
• The update covered completed formulation, delivery, and cGMP manufacturing work intended to support clinical supply for the Phase 2 program.
• Stability and product-quality testing indicated the drug substance and gel formulation remained usable over extended storage periods, supporting trial readiness.
• The company positioned Nu-3 as a topical antimicrobial designed to lower the risk of resistance, with broader potential across other infectious-disease settings.
• Results have already been presented in this announcement, with the Phase 2 trial expected to be run in the future.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lakewood-Amedex Biotherapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202605180802PR_NEWS_USPR_____NY61070) on May 18, 2026, and is solely responsible for the information contained therein.